Autologous Anti-CD7 CAR T Cells PA3-17 clinical trials
Its developmentBy PersonGen BioTherapeutics (Suzhou), step by step6 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Autologous Anti-CD7 CAR T Cells PA3-17 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Anti-CD7 CAR T Cells PA3-17 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- T cell injection targeting CD7 chimeric antigen receptor
- 6
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses Autologous Anti-CD7 CAR T Cells PA3-17 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaRecruitingPhase 2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07188610Written as T cell injection targeting CD7 chimeric antigen receptor
- Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaNot yet recruitingPhase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07623681Written as T cell injection targeting CD7 chimeric antigen receptor
- Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune DiseasesNot yet recruitingNot applicablePersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT06871644Written as T cell injection targeting CD7 chimeric antigen receptor
- PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesStatus unknownPhase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT05170568Written as T cell injection targeting CD7 chimeric antigen receptor
- CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute LeukemiaStatus unknownNot applicablePersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT04785833Written as T cell injection targeting CD7 chimeric antigen receptor
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownPhase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT04480788Written as T cell injection targeting CD7 chimeric antigen receptor